Increased expression of activating factors in large osteoclasts could explain their excessive activity in osteolytic diseases.
about
siRNA knock-down of RANK signaling to control osteoclast-mediated bone resorption.Small interfering RNA knocks down the molecular target of alendronate, farnesyl pyrophosphate synthase, in osteoclast and osteoblast cultures.Positive regulators of osteoclastogenesis and bone resorption in rheumatoid arthritisMMP-13 stimulates osteoclast differentiation and activation in tumour breast bone metastases.Moderate excess of pyruvate augments osteoclastogenesis.Decoys and Regulatory "Receptors" of the IL-1/Toll-Like Receptor Superfamily.Both cell-surface and secreted CSF-1 expressed by tumor cells metastatic to bone can contribute to osteoclast activation.Breast cancer-derived factors stimulate osteoclastogenesis through the Ca2+/protein kinase C and transforming growth factor-beta/MAPK signaling pathways.Regulation of Osteoclast Growth and Fusion by mTOR/raptor and mTOR/rictor/Akt.Cytokine decoy and scavenger receptors as key regulators of immunity and inflammation.Location matters: osteoblast and osteoclast distribution is modified by the presence and proximity to breast cancer cells in vivo.Estrogen withdrawal transiently increased bone turnover without affecting the bone balance along the tooth socket in rats.Generation of a novel mouse model for the inducible depletion of macrophages in vivo.Decoy receptor 3 suppresses RANKL-induced osteoclastogenesis via down-regulating NFATc1 and enhancing cell apoptosis.Dual impact of live Staphylococcus aureus on the osteoclast lineage, leading to increased bone resorption.Tuning inflammation and immunity by the negative regulators IL-1R2 and IL-1R8.Monocytes from patients with osteoarthritis display increased osteoclastogenesis and bone resorption: the In Vitro Osteoclast Differentiation in Arthritis study.Periodontal reconstruction by heparan sulfate mimetic-based matrix therapy in -infected mice
P2860
Q33912421-8C828718-AB0D-4C23-80C8-CF2CA92D2923Q34890347-30690355-0524-46E2-8E8E-8C37AA247061Q35617594-3DC7B6F7-E866-430E-955F-9C8ED30DF19BQ35683612-1EEA943A-DD1A-4078-B1CB-48EA21690F8AQ36764302-D2F9E86D-0A10-4C71-A1B8-E4952F7CE1A0Q36994635-4590DAE9-6305-4276-B9D3-15F22BE933F7Q37246530-C45A4850-5022-4AC7-A126-C587C2A6AE99Q37446271-53E72237-B800-4B0D-BEAB-4623484359B5Q38749702-A4B1138C-A08E-4CD9-9819-659D5FDC0229Q38920969-D78ADCFE-C244-4FFA-BBD7-4288A2AE97FDQ39352902-F09B2DA7-CA3B-4812-AD05-6D77A71C7CFDQ42463926-940FCD99-07AE-49BE-881A-471B647CB083Q43814054-86385F74-12C8-4EFB-B86A-1D415E6D3125Q44496075-DDA34331-14D9-4BA1-9E35-C0357D2A2801Q44895112-16B7CFEE-0408-4A90-943D-D3605384C6A1Q47285918-B4814C37-38E3-4E6A-BE92-A3BDDFA34DD0Q54288752-394F9DB5-83B5-4867-A02F-B8B9C8EC43CAQ58799277-AB4F49E2-3064-435A-B752-111F3260B811
P2860
Increased expression of activating factors in large osteoclasts could explain their excessive activity in osteolytic diseases.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Increased expression of activa ...... tivity in osteolytic diseases.
@en
type
label
Increased expression of activa ...... tivity in osteolytic diseases.
@en
prefLabel
Increased expression of activa ...... tivity in osteolytic diseases.
@en
P2093
P356
P1476
Increased expression of activa ...... tivity in osteolytic diseases.
@en
P2093
Azza Gramoun
Diana P Trebec
Divya Chandra
Johan N M Heersche
Morris F Manolson
P304
P356
10.1002/JCB.21171
P577
2007-05-01T00:00:00Z